mitoxantrone has been researched along with Stomach Neoplasms in 28 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "16 patients with cytologically verified malignant pericardial effusions (8 with bronchial carcinoma, 7 with carcinoma of the breast, 1 with adenocarcinoma of the stomach) received an intrapericardial instillation of mitoxantrone 1-3 x10-20 mg." | 7.72 | Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion. ( Chrissafidou, A; Gremmler, B; Malek, M; Musch, E; Nitsch, J; Rieger, J, 2003) |
| " At concentrations of 10-50 microM, TPS-A reversed a mitoxantrone-resistant phenotype and inhibited the cellular BCRP-dependent mitoxantrone accumulation in the human gastric carcinoma cell line EPG85-257RNOV, the human breast cancer cell line MCF7/AdrVp (both exhibiting acquired BCRP-mediated MDR) and the BCRP cDNA-transfected breast cancer cell line MCF-7/BCRP clone 8." | 7.72 | Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. ( Herrmann, A; Lage, H; Osada, H; Woehlecke, H, 2003) |
| "A variety of drug-resistant human cancer cell lines derived by selection with mitoxantrone markedly overexpressed BCRP mRNA; these cell lines included sublines of human breast carcinoma (MCF-7), colon carcinoma (S1 and HT29), gastric carcinoma (EPG85-257), fibrosarcoma (EPF86-079), and myeloma (8226) origins." | 7.70 | Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. ( Abruzzo, LV; Cole, SP; Dalton, WS; Dietel, M; Doyle, LA; Greenberger, L; Lage, H; Ross, DD; Schneider, E; Yang, W, 1999) |
| "Sixteen patients with advanced adenocarcinoma of the stomach were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals." | 5.06 | A phase II study of mitoxantrone in advanced gastric cancer. ( Gill, PG; Levi, JA; Presgrave, P, 1990) |
| "We analyzed the impact of candidone, tephrosin, and bavachinin, as chemosensitizer on cell cytotoxicity, P-gp and ABCG2 mRNA expression level on two multidrug resistant cells, ABCG2 overexpressing human epithelial breast cancer cell line (MCF7/MX), and P-gp overexpressing human gastric adenocarcinoma cell line (EPG85." | 4.02 | Improvement of cytotoxicity of mitoxantrone and daunorubicin by candidone, tephrosin, and bavachinin. ( Aali, E; Darzi, S; Elahian, F; Mirzaei, SA; Peymani, A; Pishkhan Dibazar, S; Rahmani, B; Shakeri Chaleshtori, L; Shirian, S, 2021) |
| "16 patients with cytologically verified malignant pericardial effusions (8 with bronchial carcinoma, 7 with carcinoma of the breast, 1 with adenocarcinoma of the stomach) received an intrapericardial instillation of mitoxantrone 1-3 x10-20 mg." | 3.72 | Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion. ( Chrissafidou, A; Gremmler, B; Malek, M; Musch, E; Nitsch, J; Rieger, J, 2003) |
| " At concentrations of 10-50 microM, TPS-A reversed a mitoxantrone-resistant phenotype and inhibited the cellular BCRP-dependent mitoxantrone accumulation in the human gastric carcinoma cell line EPG85-257RNOV, the human breast cancer cell line MCF7/AdrVp (both exhibiting acquired BCRP-mediated MDR) and the BCRP cDNA-transfected breast cancer cell line MCF-7/BCRP clone 8." | 3.72 | Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. ( Herrmann, A; Lage, H; Osada, H; Woehlecke, H, 2003) |
| "A variety of drug-resistant human cancer cell lines derived by selection with mitoxantrone markedly overexpressed BCRP mRNA; these cell lines included sublines of human breast carcinoma (MCF-7), colon carcinoma (S1 and HT29), gastric carcinoma (EPG85-257), fibrosarcoma (EPF86-079), and myeloma (8226) origins." | 3.70 | Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. ( Abruzzo, LV; Cole, SP; Dalton, WS; Dietel, M; Doyle, LA; Greenberger, L; Lage, H; Ross, DD; Schneider, E; Yang, W, 1999) |
| "To evaluate the efficacy of postoperative intraperitoneal hyperthermic chemoperfusion (IHCP) combined with intravenous chemotherapy for advanced gastric cancer." | 2.71 | [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. ( Lu, JF; Lu, WD; Shen, D; Xu, M; Zuo, Y, 2004) |
| "Patients with stage II and III gastric cancer aged between 15 and 70 years, after curative resection, with adequate liver, renal, and cardiac function were included in the study." | 2.70 | Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study. ( Argon, A; Aydiner, A; Aykan, NF; Basaran, M; Bugra, D; Saip, P; Sakar, B; Tas, F; Topuz, E; Uygun, K, 2002) |
| "Objective response rates were 21% in breast cancer, 36% in non-Hodgkin's lymphoma, 56% in acute lymphocytic leukemia, 14% in acute nonlymphocytic leukemia, 31% in gastric cancer and 5% in primary hepatic cancer." | 2.66 | [Phase II clinical trial on mitoxantrone]. ( Gao, HR, 1989) |
| "Mitoxantrone was administered intravenously at a dose of 14 mg/m2 every 3 weeks." | 2.66 | Phase II trial of mitoxantrone in advanced gastric cancer. ( Benedetto, P; Goldenberg, A; Kelsen, D, 1988) |
| "Mitoxantrone accumulation was also amplified in IL-1β-, IL-6- or TNF-α-treated HeLa cells and in IL-1β-treated EPG85-257 cells." | 1.38 | Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells. ( Afshari, JT; Behravan, J; Kalalinia, F; Lage, H; Mosaffa, F, 2012) |
| "We present a patient with MALT lymphoma of the salivary glands who also had multiple calculi in the parotid glands." | 1.33 | Multiple bilateral parotid sialoliths in a patient with mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) of the salivary glands. ( Drage, NA; Howarth, A; Wickramasinghe, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (25.00) | 18.7374 |
| 1990's | 6 (21.43) | 18.2507 |
| 2000's | 13 (46.43) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Darzi, S | 1 |
| Mirzaei, SA | 1 |
| Elahian, F | 1 |
| Peymani, A | 1 |
| Rahmani, B | 1 |
| Pishkhan Dibazar, S | 1 |
| Shirian, S | 1 |
| Shakeri Chaleshtori, L | 1 |
| Aali, E | 1 |
| Mosaffa, F | 1 |
| Kalalinia, F | 1 |
| Lage, H | 12 |
| Afshari, JT | 1 |
| Behravan, J | 1 |
| Topuz, E | 1 |
| Basaran, M | 1 |
| Saip, P | 1 |
| Aydiner, A | 1 |
| Argon, A | 1 |
| Sakar, B | 1 |
| Tas, F | 1 |
| Uygun, K | 1 |
| Bugra, D | 1 |
| Aykan, NF | 1 |
| Tönnies, H | 1 |
| Poland, J | 1 |
| Sinha, P | 3 |
| Musch, E | 1 |
| Gremmler, B | 1 |
| Nitsch, J | 1 |
| Rieger, J | 1 |
| Malek, M | 1 |
| Chrissafidou, A | 1 |
| Woehlecke, H | 1 |
| Osada, H | 1 |
| Herrmann, A | 1 |
| Wichert, A | 1 |
| Stege, A | 1 |
| Midorikawa, Y | 1 |
| Holm, PS | 1 |
| Zuo, Y | 1 |
| Xu, M | 1 |
| Shen, D | 1 |
| Lu, WD | 1 |
| Lu, JF | 1 |
| Wickramasinghe, A | 1 |
| Howarth, A | 1 |
| Drage, NA | 1 |
| Györffy, B | 1 |
| Serra, V | 1 |
| Jürchott, K | 1 |
| Abdul-Ghani, R | 1 |
| Garber, M | 1 |
| Stein, U | 3 |
| Petersen, I | 1 |
| Dietel, M | 7 |
| Schäfer, R | 1 |
| Wöhrer, S | 1 |
| Bartsch, R | 1 |
| Hejna, M | 1 |
| Drach, J | 1 |
| Raderer, M | 1 |
| Bedikian, AY | 1 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Kellner, U | 1 |
| Hutchinson, L | 1 |
| Seidel, A | 1 |
| Danks, MK | 1 |
| Kaufmann, SH | 1 |
| Hütter, G | 1 |
| Köttgen, E | 1 |
| Schadendorf, D | 2 |
| Ross, DD | 1 |
| Yang, W | 1 |
| Abruzzo, LV | 1 |
| Dalton, WS | 1 |
| Schneider, E | 1 |
| Greenberger, L | 1 |
| Cole, SP | 1 |
| Doyle, LA | 1 |
| Novik, Y | 1 |
| Ryan, LM | 1 |
| Haller, DG | 1 |
| Asbury, R | 1 |
| Dutcher, JP | 1 |
| Schutt, A | 1 |
| Ruiz Hernández, G | 1 |
| Pallardó-Calatayud, J | 1 |
| Ferrer Albiach, C | 1 |
| Balaguer-Martínez, JV | 1 |
| Romero-de-Avila, C | 1 |
| Castillo-Pallarés, FJ | 1 |
| Perlitz, C | 1 |
| Abele, R | 1 |
| Tampé, R | 1 |
| Jordan, A | 1 |
| Walther, W | 1 |
| Bates, SE | 1 |
| Litman, T | 1 |
| Hohenberger, P | 1 |
| Kowalski, P | 1 |
| Scheffer, GL | 1 |
| Arps, H | 1 |
| Niendorf, A | 1 |
| Levi, JA | 1 |
| Gill, PG | 1 |
| Presgrave, P | 1 |
| Mulder, PO | 1 |
| Sleijfer, DT | 1 |
| Willemse, PH | 1 |
| de Vries, EG | 1 |
| Uges, DR | 1 |
| Mulder, NH | 1 |
| Navarrete, E | 1 |
| Rodier, JF | 1 |
| Janser, JC | 1 |
| Haegele, P | 1 |
| Pusel, J | 1 |
| Rodier, D | 1 |
| Gao, HR | 1 |
| Bai, SH | 1 |
| Xu, G | 1 |
| Tang, P | 1 |
| Chen, XH | 1 |
| Goldenberg, A | 1 |
| Kelsen, D | 1 |
| Benedetto, P | 1 |
| DeSimone, PA | 1 |
| Gams, R | 1 |
| Birch, R | 1 |
1 review available for mitoxantrone and Stomach Neoplasms
| Article | Year |
|---|---|
[Gastric metastases of cancer of the breast. Apropos of a case. Review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Combined | 1989 |
7 trials available for mitoxantrone and Stomach Neoplasms
| Article | Year |
|---|---|
Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2002 |
[Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2004 |
Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.
Topics: Aclarubicin; Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 1999 |
A phase II study of mitoxantrone in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Evaluation; Humans; Middle Aged; Mitoxantrone; | 1990 |
[Phase II clinical trial on mitoxantrone].
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Drug Evaluation; Female; Humans; Leukopenia; Lymphoma, No | 1989 |
Phase II trial of mitoxantrone in advanced gastric cancer.
Topics: Adult; Aged; Agranulocytosis; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middl | 1988 |
Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group Trial.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Clinical Trials | 1986 |
20 other studies available for mitoxantrone and Stomach Neoplasms
| Article | Year |
|---|---|
Improvement of cytotoxicity of mitoxantrone and daunorubicin by candidone, tephrosin, and bavachinin.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Membe | 2021 |
Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2012 |
Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, M | 2003 |
Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, | 2003 |
Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.
Topics: Acridines; Antineoplastic Agents; Breast Neoplasms; Cell Division; Daunorubicin; Drug Resistance, Mu | 2003 |
Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Cell Line, Tumor; DNA Primers; Flow Cytometry; Glyp | 2004 |
Multiple bilateral parotid sialoliths in a patient with mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) of the salivary glands.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female | 2005 |
Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; | 2005 |
Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2005 |
Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukocyte Count | 1983 |
Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; D | 1997 |
Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells.
Topics: Annexin A1; Antibiotics, Antineoplastic; Antineoplastic Agents; Daunorubicin; Drug Resistance, Multi | 1998 |
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Topics: Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Breast Neoplasms; Colonic Neoplasms; | 1999 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combi | 2001 |
Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP Binding Cassette | 2001 |
Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, M | 2002 |
Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding C | 2002 |
Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Drug Resistance; Humans; Mem | 1990 |
High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
Topics: Adult; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Female; Humans; Male; Melpha | 1989 |
[A study of antineoplastic activity of DHAQ on human adenocarcinoma cells of lung hepatoma and gastric cancer cells in vitro].
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Cell Line; Humans; Liver Neoplasms; Lung Neoplasms; Mitot | 1986 |